Format

Send to

Choose Destination
Nat Commun. 2019 May 28;10(1):2340. doi: 10.1038/s41467-019-10275-0.

SORLA regulates endosomal trafficking and oncogenic fitness of HER2.

Author information

1
Turku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland. mika.pietila@utu.fi.
2
Turku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland.
3
Danish Research Institute of Translational Neuroscience Nordic-EMBL Partnership (DANDRITE), Department of Biomedicine, Aarhus University, Ole Worms Allé 3, 8000, Aarhus, Denmark.
4
Laboratory of Molecular Oncology, Translational Cancer Biology Program, University of Helsinki and Comprehensive Cancer Center, Helsinki University Hospital, FI-00290, Helsinki, Finland.
5
Institute of Biomedicine, University of Turku and Department of Pathology, Turku University Hospital, FI-20520, Turku, Finland.
6
Department of Urology, University of Turku and Turku University Hospital, FI-20520, Turku, Finland.
7
Turku Bioscience Centre, University of Turku and Åbo Akademi University, FI-20520, Turku, Finland. Johanna.ivaska@utu.fi.
8
Department of Biochemistry, University of Turku, FI-20520, Turku, Finland. Johanna.ivaska@utu.fi.

Abstract

The human epidermal growth factor receptor 2 (HER2) is an oncogene targeted by several kinase inhibitors and therapeutic antibodies. While the endosomal trafficking of many other receptor tyrosine kinases is known to regulate their oncogenic signalling, the prevailing view on HER2 is that this receptor is predominantly retained on the cell surface. Here, we find that sortilin-related receptor 1 (SORLA; SORL1) co-precipitates with HER2 in cancer cells and regulates HER2 subcellular distribution by promoting recycling of the endosomal receptor back to the plasma membrane. SORLA protein levels in cancer cell lines and bladder cancers correlates with HER2 levels. Depletion of SORLA triggers HER2 targeting to late endosomal/lysosomal compartments and impairs HER2-driven signalling and in vivo tumour growth. SORLA silencing also disrupts normal lysosome function and sensitizes anti-HER2 therapy sensitive and resistant cancer cells to lysosome-targeting cationic amphiphilic drugs. These findings reveal potentially important SORLA-dependent endosomal trafficking-linked vulnerabilities in HER2-driven cancers.

PMID:
31138794
PMCID:
PMC6538630
DOI:
10.1038/s41467-019-10275-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center